DAPA HF, DAPAGLIFLOZIN HEART FAILURE TRIAL SHOWED CONSISTENT RESULTS.

Dear my friends and fellow Colleagues, Here is an update on DAPA HF Trial. Dapagliflozin Effect is Consistent in HFrEF Regardless of Background Therapy based on DAPA-HF Trial. Reference Docherty KF et al. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. Eur Heart J. 2020; ehaa183:1-13. Regards and thanks, Dr Sepuri Krishna Mohan.

3 Likes

LikeAnswersShare

As usual wonderful update Dr Mohan. Though DAPAGLIFLOZIN is not so effective in preventing 3 point MACE . It is exceptionally good in reducing hospitalization for heart failure with reduced ejection fraction. It significantly improves systolic dysfunction in patients with heart failure. It decreases the worsening of renal function . It was associated with reduction in recurrent heart failure events and also associated with improvement in symptoms. The weight reduction is significant with DAPAGLIFLOZIN compared to other SGLT2 Inhibitors in my clinical experience.

Wonderful & Valuable inputs Dr Devi.
0

Yes sir results are consistent with Carolina trial

Dear Sir, CAROLINA was a trial done with LINAGLIPTIN and the active comparator was GLIMEPIRIDE. Regards and thanks sir, Dr Sepuri Krishna Mohan
0

Thanx sir

You're most welcome dear Sir
0